A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS).
Saved in:
| Title: | A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). |
|---|---|
| Authors: | Ostermann M; Critical Care and Nephrology, NHS Foundation Trust, Guy's and St Thomas, London, UK., Corteville DC; Department of Cardiology, Rochester Regional Health, Rochester, USA., Doi K; Emergency and Critical Care Medicine, The University of Tokyo Hospital, Tokyo, Japan., Koyner JL; Section of Nephrology, The University of Chicago, Chicago, USA., Lamy A; Division of Cardiac Surgery and Population Health Research Institute, McMaster University, Hamilton, Canada., Li G; Alexion, AstraZeneca Rare Disease, Boston, USA., Solinsky CM; Alexion, AstraZeneca Rare Disease, Boston, USA. christine.solinsky@alexion.com., Winterberg PD; Alexion, AstraZeneca Rare Disease, Boston, USA.; Present Address: Vera Therapeutics, Brisbane, USA., Smith WT; Alexion, AstraZeneca Rare Disease, Boston, USA.; Present Address: Novartis, East Hanover, USA., Mehta RL; Department of Medicine, San Diego School of Medicine, University of California, San Diego, USA., Murray PT; University College Dublin Clinical Research Centre, UCD School of Medicine, Dublin, Ireland., Shaw AD; Department of Intensive Care and Resuscitation, Cleveland Clinic, Cleveland, USA.; Present Address: Critical Care and ECMO Division of ABIOMED, J&J MedTech, Cleveland, USA., Zarbock A; Department of Anesthesiology, Intensive Care and Pain Medicine, University of Münster, Münster, Germany., Engelman DT; Heart & Vascular Program Baystate Health, University of Massachusetts Chan Medical School-Baystate, Springfield, USA. |
| Source: | Trials [Trials] 2025 May 30; Vol. 26 (1), pp. 181. Date of Electronic Publication: 2025 May 30. |
| Publication Type: | Journal Article; Clinical Trial Protocol |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1745-6215 |
|---|---|
| DOI: | 10.1186/s13063-025-08895-7 |
